Conditions: Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: regorafenib
Intervention descriptions: intervention 1: Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment

Protocol document: